PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
August 30, 2012 | ISSUE NUMBER 266 VOL 8

Regulatory
Taxpayers and Embryonic Stem Cell Research
Last Friday, an appellate court upheld an earlier judgment allowing government to fund embryonic stem cell research for the development of new therapies. Stem cell biotechs and industry groups cheered the decision but uncertainty remains, in large part due to the possibility of a Romney administration in the White House
...Read more

Corporate Social Responsibility
Good Policy: The Victim of 'Good Works'?
The decision by many leading companies to merge the corporate social responsibility (CSR) function with public policy/government relations advocacy — effectively subordinating the latter tasks as part of a "reputation management" mandate focused on philanthropy and good works — threatens to do serious damage to the industry's chances in preserving its basic "license to operate"
...Read More

Global
European Union Pins Hopes on HTA for Consensus on Value
The European Union's proposed health technology assessment network to encourage "cooperation and exchange of scientific information among member states" is a significant step, says Reflector. But, as far as standardizing an approach to value is concerned, will it be a damp squib? ...Read More

Advertisement
Pharmaceutical companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. Varied demography, varied government spending on health and differences in the regulatory environments in individual countries of the emerging markets require global pharmaceutical companies to create and implement specific and custom strategies to succeed in these markets.

The whitepaper examines the current trends, requirements and outsourcing solutions for effective medical communication approach for the emerging markets.
www.sciformix.com/ROI.php

Sales
Why Sales Forces are Being Revived
Eric Janvier and Wendy van der Lubbe ask how traditional sales forces can be best utilized in a new model of customer-centric engagement
...Read more

// Aragon Pharmaceuticals (San Diego, CA) announced the appointment of Faheem Hasnain as an independent director of the company's board of directors. // Venture capital firm Lux Capital (New York, NY) appointed former Pfizer Chairman and Chief Executive Jeff Kindler as a partner. // Communications firm Hill+Knowlton Strategies appointed Susan Thiele as Healthcare Practice Leader. // Optimal Strategix Group (Newtown, PA), announced that Dr Ajit Shetty, Chairman Emeritus of the Board of Directors of Janssen Pharmaceutica and former Corporate Vice President, Enterprise Supply Chain at Johnson & Johnson, has joined its Board of Directors.

September 13: Healthcare Businesswomen's Association Boston Chapter Healthcare Forum: Impact of Healthcare Reform on Innovation
Boston, MA


September 20–21: 3rd Annual Forum on Strategic Distribution Planning for Specialty Products
East Brunswick, NJ


October 17–18: 2nd Annual Global Transparency Reporting Congress
Amsterdam, The Netherlands

Advertisement
Meeting Global Patient Demand for Access to Medicines Prior to Approval and Launch
On-Demand Webcast
http://pharmexec.com/demand

 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook



Survey
Should FDA be forced to make changes to how it regulates the drug industry?

Click To Vote
 
Quick Links

Paul Ryan and Pharma: The Inside Story

Sunny Outlook for Biopharma 2020?

Pfizer and Mylan to Develop Generic Drugs in Japan


User Management
| Subscribe | Update My Profile | Advertise With Us | Visit PharmExec.com |